Short-term effects of Sipulin combined with radiotherapy on local advanced non-small cell lung cancer and its influence on immune function
- Author:
Tie-Jun WANG
1
Author Information
1. Radiation Oncology of the Second Hospital
- Publication Type:Journal Article
- Keywords:
Carcinoma;
Immunity;
Non-samll-cell lung;
Radiotherapy;
Sipulin
- From:
Tumor
2007;27(6):493-495
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observed the short-term effects of Sipulin combined with radiotherapy on local advanced non small-cell lung cancer (NSCLC) and its influence on the immune function. Methods: Ninety patients with local advanced NSCLC were randomly divided into trial group (Sipulin plus radiotherapy) and the control group (only radiotherapy). The patients in trial group were given Sipulin (10 mL/d, 25 mg peptide) by Bolus infusion combined with radiotherapy for 4 weeks. The patients in control group received only radiotherapy at the same dosage. All the patients were followed up for 2 years. The follow up ratio was 100%. Results:(1) The response ratio was 66.7% and 33.3% in trial group and control group, respectively (P < 0.05). The one-year survival rate was 71.1% and 44.4% respectively (P <0.05). (2) The life quality of the patients in trial group was much better than that in control group (P<0.05). (3) The population of CD3+ cells, CD4+ cells and the ratio of CD4+/CD8+ were increased but the population of CD8+ cells were decreased after combined treatment. The population of CD3+ cells, CD4+ cells and the ratio of CD4+/CD8+ were decreased but the population of CD8+ cells were increased after single radiotherapy (P < 0.05). Compared with control group, combined treatment induced a marked rise in the population of CD3+ cells and CD4+ cells and the ratio of CD4+/CD8+ and a fall in the population of CD8+ cells (P < 0.01). Conclusion: The short-term effect of Sipulin combined with radiotherapy on local advanced NSCLC is better than that of single radiotherapy. Combined therapy could improve the life quality and enhance the immune function of the NSCLC patients.
